First report of a bla NDM-producing extensively drug resistant Klebsiella pneumoniae ST437 in Italy

Front Cell Infect Microbiol. 2024 Sep 11:14:1426817. doi: 10.3389/fcimb.2024.1426817. eCollection 2024.

Abstract

Carbapenemase-producing Klebsiella pneumoniae strains (CP-Kps) have recently been observed to spread rapidly worldwide. New Delhi metallo-β-lactamase (NDM) producing clones of Klebsiella pneumoniae (K. pneumoniae) cause a significant healthcare burden, particularly in Indian sub-continent, where this clone is circulating widely. However, in Italy, data on the incidence of these new clones is limited, and an ST437 NDM-producing K. pneumoniae strain has not been reported to date. A sacral ulcer infection caused by a K. pneumoniae strain was identified in an 85-year-old Italian male patient with several comorbidities. Antimicrobial susceptibility testing revealed an extensive resistance to a wide range of antimicrobials, including novel agents such as cefiderocol and ceftazidime/avibactam. Genomic analysis identified the pathogen as an ST437 K. pneumoniae strain harboring bla NDM-5, bla OXA-232 and bla CTX-M-15 genes. Following the identification of this first case, several infection control measures were implemented in healthcare settings, including direct precautions and reinforcement of standard cross-transmission control measures. The emergence of pathogenic microbial clones carrying new genetic determinants, particularly in a little city, requires prompt diagnosis and therapeutic protocols. An effective infection control system for the early detection and/or control of the transmission of NDM-producing Enterobacteriaceae is also needed. Further investigations are required to better understand the potential transmission routes and evolution of these clones.

Keywords: Klebsiella pneumoniae; New Delhi metallo-β-lactamase; carbapenemase-producing pathogen; ceftazidime/avibactam; whole genome sequencing (WGS).

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Azabicyclo Compounds
  • Bacterial Proteins / genetics
  • Bacterial Proteins / metabolism
  • Ceftazidime / pharmacology
  • Ceftazidime / therapeutic use
  • Drug Combinations
  • Drug Resistance, Multiple, Bacterial* / genetics
  • Humans
  • Infection Control
  • Italy
  • Klebsiella Infections* / drug therapy
  • Klebsiella Infections* / microbiology
  • Klebsiella pneumoniae* / drug effects
  • Klebsiella pneumoniae* / enzymology
  • Klebsiella pneumoniae* / genetics
  • Klebsiella pneumoniae* / isolation & purification
  • Male
  • Microbial Sensitivity Tests*
  • Whole Genome Sequencing
  • beta-Lactamases* / genetics
  • beta-Lactamases* / metabolism

Substances

  • beta-Lactamases
  • Anti-Bacterial Agents
  • beta-lactamase NDM-1
  • Bacterial Proteins
  • beta-lactamase CTX-M-15
  • avibactam, ceftazidime drug combination
  • Ceftazidime
  • beta-lactamase OXA-232, Klebsiella pneumoniae
  • Drug Combinations
  • Azabicyclo Compounds

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was supported by EU funding within the NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT).